Social Determinants of SUD Treatment Outcomes in a Vulnerable Population - Project Summary/Abstract
Substance use disorders (SUD) disproportionately affect multiple vulnerable populations,
including individuals with mental health problems. Although it had been long assumed that SUD
risks are not elevated among individuals with autism spectrum disorders, recent publications,
including those in JAMA, highlighted, on the contrary, a disproportionate vulnerability to SUD
among youth and adults with autism spectrum disorder (ASD), as independently reported in
several international studies. For example, in a study of individuals with SUD in Taiwan, the
presence of ASD was shown to triple mortality rates, increase severity of SUD symptoms and
escalate their progression. In the US, very little is known about the elevated vulnerability to SUD
among youth and adults with ASD, potentially creating a “hidden” vulnerable population
underserved by the current substance use treatment systems.
The overall goal of the proposed study is to analyze the world’s largest healthcare data set, the
US national Medicaid data, to (1) compare the likelihood of having various SUDs among
individuals with and without ASD, aged 11 and older; and (2) analyze differences in SUD
treatment usage and SUD severity among substance-using individuals with and without ASD.
To identify malleable moderators of the above relationships, we will for the first time merge
Medicaid patient with data on patients’ social determinants of health (e.g. social isolation and
economic instability) from TransUnion, a national repository of individual-level socio-economic
data (available only for adults). We will also test moderating effects of state policies regarding
reimbursement of specific SUD and ASD interventions.
More specifically, the proposed study will examine whether SUD prevalence, severity, patterns
and SU- related adverse events are exacerbated by ASD status. It will also examine the role of
social determinants of health, demographic factors, and state-level treatment policies in
buffering or amplifying the effects of ASD on substance use related outcomes.